Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
A frameless srs patient treatment was planned with brainlab iplan rt dose 4.1.3. the plan was intended for treatment of intra-cranial metastatic lesions located in 3 different regions/isocenters. the customer prescribed 100% dose to 99% of the volume to all three ptvs (defined as "hard constraints").